Recipients of third round of Medicine by Design’s Pivotal Experiment Fund announced
Fund advances research discoveries to real benefit for human health
Fund advances research discoveries to real benefit for human health
Is immunoengineering the key to ensuring that cell therapies can treat disease?
Medicine by Design-funded research program that aims to generate next-generation immunomodulation therapies has seeded a Canadian biotechnology success story with the closing of an $85-million (U.S.) Series A financing.
Medicine by Design is expanding its regenerative medicine research portfolio with the addition of four multi-disciplinary, multi-institution projects. “These team projects build on Medicine by Design’s successes over its first three years and will strengthen the University of Toronto and its affiliated hospitals as a global centre for regenerative medicine,” said Michael Sefton, executive director of Medicine by Design.